Overview
COCP market data
Price History
COCP price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.80 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.55 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,021.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.76 – $2.67 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $15.2M · P/B 2.13 · P/S 67.41.
Company News
Cocrystal Pharma Q2 EPS $(0.23) Misses $(0.17) Estimate, Sales $105.000KBenzinga · Aug 13, 2026, 12:23 PM
Cocrystal Pharma shares are trading higher after the company announced a $5 million private placement with OPKO Health.Benzinga · Aug 3, 2026, 2:22 PM
8-K filing — Cocrystal Pharma, Inc. (COCP)SEC EDGAR · Aug 3, 2026, 11:15 AM
Cocrystal Pharma Secures $5M Investment From OPKO Health To Advance Norovirus Program Toward Phase 1b DataBenzinga · Aug 3, 2026, 11:01 AM
Cocrystal Pharma's Direct-Acting Antivirals Demonstrate Pan-Viral Activity Against Multiple Viruses, Including Hantavirus, Bunyavirus And InfluenzaBenzinga · May 26, 2026, 12:09 PM
Cocrystal Pharma Q1 EPS $(0.17) Misses $(0.15) Estimate, Sales $225.000KBenzinga · May 15, 2026, 12:15 PM
Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial ResultsGlobenewswire Inc · May 15, 2026, 12:15 PM